Dual-responsive magnetic vortex nanorings co-deliver lenvatinib and localized heat for synergistic activation of antitumor immunity
Acta Biomaterialia · 2025-05 · 198 · 389-400
DOI: 10.1016/j.actbio.2025.04.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2025-05. Verfasst von Zirui Ye und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, Shaanxi Province Center for Regenerative Medicine and…. Hauptthemen laut MEDLINE: Phenylurea Compounds, Quinolines, Carcinoma, Hepatocellular, Hyperthermia, Induced. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) presents significant treatment challenges, primarily due to its ability to suppress immune responses. Lenvatinib (LT), approved as a first-line therapy for HCC, modulates the immune microenvironment by reducing PD-L1 expression and decreasing the infiltration of regulatory T cells (Tregs) within the tumor. However, the low immunogenicity of HCC and high toxicity of LT often undermine its effectiveness. To address these challenges, polydopamine (PDA)-coated ferrimagnetic vortex-domain iron oxide nanorings (FVIO@PDA) were engineered to respond to both acidic conditions and magnetic fields, facilitating the simultaneous delivery of the drug (LT) and a physio-therapeutic heat modality. The dual-responsive nature of FVIO@PDA ensures a controlled and synergistic release of LT, activated by acidic tumor microenvironments and the heat produced by an alternating magnetic field (AMF). In a subcutaneous Hepa1-6 HCC model, LT-loaded FVIO@PDA-PEG (denoted as LT-loaded FPP)-mediated magnetic hyperthermia significantly increased the levels of cytotoxic T lymphocytes, showing an approximate 3.86-fold increase compared to the control groups. This combination of LT and magnetic hyperthermia also reduced Treg populations to 1.4 %, synergistically triggering a robust antitumor immune response. Additionally, it altered cytokine profiles, reducing the secretion of the immunosuppressive cytokine IL-10 to 0.41 times that of control levels, while increasing the secretion of pro-inflammatory cytokines IFN-γ and TNF-α by 3.25 and 4.34 times, respectively. Furthermore, LT-loaded FPP-mediated magnetic hyperthermia exhibits superior anti-tumor activity compared to either treatment alone. These results highlight the promise of combining LT with FPP-mediated immunogenic magnetic hyperthermia as a potent therapeutic strategy for HCC, offering a more effective approach to modulate the immune environment and enhance antitumor efficacy. STATEMENT OF SIGNIFICANCE: Lenvatinib (LT) is a selective multi-targeted tyrosine kinase inhibitor used for patients with unresectable HCC who have not previously undergone systemic therapy. LT's immunomodulatory effects alone are often insufficient to induce an effective immune response, and treatment outcomes continue to be unsatisfactory. We developed FVIO@PDA for the delivery of LT and localized heat. FVIO@PDA allowed for controlled release of LT, triggered by the acidic tumor microenvironment and the heat generated under an AMF. LT combined with magnetic hyperthermia increased CTLs, reduced Tregs, decreased immunosuppressive cytokines, and elevated pro-inflammatory ones, collectively initiating a strong antitumor immune response. LT combined with magnetic hyperthermia showed superior antitumor effect compared to either treatment alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine, Shaanxi Province Center for Regenerative Medicine and Surgery Engineering Research, Shaanxi Provincial Key Laboratory of Ma…
- School of Future Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China.
- Center for Nanomedicine and Engineering, Northwest University, Xi'an, 710127, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Ye, Z., Yan, B., Li, H., Tang, Q., Yuan, K., Hou, J., Xu, L., Yuan, J., Wang, S., Jiao, W., Fan, H., Lyu, Y., Wang, B., & Liu, X. (2025). Dual-responsive magnetic vortex nanorings co-deliver lenvatinib and localized heat for synergistic activation of antitumor immunity. Acta Biomaterialia, 198, 389-400. https://doi.org/10.1016/j.actbio.2025.04.014
Vancouver
Ye Z, Yan B, Li H, Tang Q, Yuan K, Hou J, et al. Dual-responsive magnetic vortex nanorings co-deliver lenvatinib and localized heat for synergistic activation of antitumor immunity. Acta Biomaterialia. 2025;198:389-400. doi:10.1016/j.actbio.2025.04.014
BibTeX
@article{Ye2025,
author = {Ye, Zirui and Yan, Bin and Li, Hugang and Tang, Qianqian and Yuan, Kexin and Hou, Jingjing and Xu, Lexuan and Yuan, Jianlan and Wang, Siyao and Jiao, Wangbo and Fan, Haiming and Lyu, Yi and Wang, Bo and Liu, Xiaoli},
title = {Dual-responsive magnetic vortex nanorings co-deliver lenvatinib and localized heat for synergistic activation of antitumor immunity},
journal = {Acta Biomaterialia},
year = {2025},
volume = {198},
pages = {389--400},
doi = {10.1016/j.actbio.2025.04.014}
}
EUVIMED